 Akcea Therapeutics, Inc. NASDAQ: AKCA, a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced the Portuguese Medicine Regulatory Authority INFARMED has granted approval for reimbursement of TEGSEDI inotersen for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin hATTR amyloidosis. 